Treatment strategies for elderly patients with multiple myeloma

Abstract

Multiple myeloma is a disease that predominantly affects the elderly. Given the anticipated increase in the elderly population, the treatment of multiple myeloma in elderly patients is becoming increasingly important. The treatment of elderly multiple myeloma patients requires a strategy that not only considers the efficacy of therapy but also emphasizes well-being, including performance status (PS), quality of life (QOL), and respect for the patient’s perspectives on treatment. In recent years, improvements in physical fitness among older adults and the advent of novel agents, such as anti-CD38 monoclonal antibodies, have markedly transformed treatment approaches compared with previous eras. However, challenges such as side effects, frailty, access to care, medical costs, and family support remain critical issues. It is essential to consider these factors and choose the best possible treatment for each patient.